Search results
Results From The WOW.Com Content Network
In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs.
The Food and Drug Administration on Friday approved a new cancer therapy that could one day transform the way a majority of aggressive and advanced tumors are treated.
With new treatments emerging from labs so rapidly, it might be time to rethink the clinical-trial system lest people be deprived of the most effective treatments available.
Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to...
Scientists working to improve the treatment and diagnosis of cancer are beginning to use AI, DNA sequencing and precision oncology among other techniques.
The results from many cutting-edge clinical trials this year are leading to promising new treatments for brain cancer, colorectal cancer, bladder cancer, endometrial cancer, and several different blood cancers.
The new treatment, which uses immune cells harvested from a patient’s tumor called tumor-infiltrating lymphocytes, exploits the body’s own natural cancer-fighting ability.
The regimen, called lifileucel, is the first TIL therapy to be approved by the US Food and Drug Administration (FDA). And it is the first immune-cell therapy to win FDA approval for treating...
MIT researchers have discovered a new way to jump-start the immune system to attack tumors, which could allow cancer immunotherapy to be used against more types of cancer.
From new bispecific antibodies that are redirecting T cells against difficult-to-treat blood cancers to new types of kinase inhibitors, selective estrogen receptor degraders (SERDs) and...